PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
11591186-3	2001	OBJECTIVE: In this study, we addressed the ability of desloratadine to inhibit the in vitro generation of interleukin (IL)-4 and IL-13 from human basophils while concurrently comparing its efficacy in preventing mediator release by these cells.	desloratadine	54-67	interleukin 4	Homo sapiens	106-124
11591186-3	2001	OBJECTIVE: In this study, we addressed the ability of desloratadine to inhibit the in vitro generation of interleukin (IL)-4 and IL-13 from human basophils while concurrently comparing its efficacy in preventing mediator release by these cells.	desloratadine	54-67	interleukin 13	Homo sapiens	129-134
11591186-8	2001	RESULTS: Desloratadine was found to be nearly six-seven times more potent in preventing the secretion of IL-4 and IL-13 induced by anti-IgE than it was at inhibiting the release of histamine and LTC(4).	desloratadine	9-22	interleukin 4	Homo sapiens	105-109
11591186-8	2001	RESULTS: Desloratadine was found to be nearly six-seven times more potent in preventing the secretion of IL-4 and IL-13 induced by anti-IgE than it was at inhibiting the release of histamine and LTC(4).	desloratadine	9-22	interleukin 13	Homo sapiens	114-119
11591186-10	2001	Desloratadine had a lesser effect regarding inhibition of the IL-13 secreted in response to IL-3 and PMA.	desloratadine	0-13	interleukin 13	Homo sapiens	62-67
11591186-10	2001	Desloratadine had a lesser effect regarding inhibition of the IL-13 secreted in response to IL-3 and PMA.	desloratadine	0-13	interleukin 3	Homo sapiens	92-96
11591186-12	2001	Finally, IL-4 mRNA accumulation was remarkably inhibited, by as much as 80%, following pretreatment with desloratadine.	desloratadine	105-118	interleukin 4	Homo sapiens	9-13
11591186-13	2001	CONCLUSION: While capable of inhibiting histamine and LTC(4) release by human basophils, desloratadine is more effective at targeting the signals regulating IL-4 and IL-13 generation in these cells.	desloratadine	89-102	interleukin 4	Homo sapiens	157-161
11591186-13	2001	CONCLUSION: While capable of inhibiting histamine and LTC(4) release by human basophils, desloratadine is more effective at targeting the signals regulating IL-4 and IL-13 generation in these cells.	desloratadine	89-102	interleukin 13	Homo sapiens	166-171
11502723-0	2001	In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes.	desloratadine	67-80	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
11502723-1	2001	The purpose of this study was to evaluate loratadine, desloratadine, and 3-OH-desloratadine as inhibitors of certain human liver cytochrome P-450 enzymes.	desloratadine	54-67	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	129-145
11454724-0	2001	Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein.	desloratadine	48-61	ATP binding cassette subfamily B member 1	Homo sapiens	67-81
11454724-3	2001	The purpose of this study was to determine, using two different methods, whether the nonsedating antihistamine loratadine (L) and its active metabolite desloratadine (DL) interact with P-gp.	desloratadine	152-165	ATP binding cassette subfamily B member 1	Homo sapiens	185-189
11496238-0	2001	Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells.	desloratadine	10-23	intercellular adhesion molecule 1	Homo sapiens	61-94
11496238-6	2001	OBJECTIVE: We have investigated the effects of desloratadine and loratadine on rhinovirus-induced ICAM-1 expression, mRNA upregulation, and promoter activation.	desloratadine	47-60	intercellular adhesion molecule 1	Homo sapiens	98-104
11496238-10	2001	RESULTS: Desloratadine and loratadine (0.1-10 micromol/L) inhibited rhinovirus-induced ICAM-1 upregulation in both primary bronchial or transformed (A549) respiratory epithelial cells.	desloratadine	9-22	intercellular adhesion molecule 1	Homo sapiens	87-93
11496238-12	2001	Desloratadine and loratadine also inhibited ICAM-1 mRNA induction caused by rhinovirus infection in a dose-dependent manner, and they completely inhibited rhinovirus-induced ICAM-1 promoter activation.	desloratadine	0-13	intercellular adhesion molecule 1	Homo sapiens	44-50
11496238-12	2001	Desloratadine and loratadine also inhibited ICAM-1 mRNA induction caused by rhinovirus infection in a dose-dependent manner, and they completely inhibited rhinovirus-induced ICAM-1 promoter activation.	desloratadine	0-13	intercellular adhesion molecule 1	Homo sapiens	174-180
12768222-1	2001	A new competitive histamine H(1)-receptor antagonist with superior binding affinity at this receptor as compared with other common antihistamines, desloratadine is the active metabolite of loratadine, the most extensively used agent of this class.	desloratadine	147-160	histamine receptor H1	Homo sapiens	18-41
12768222-10	2001	In addition, beta(2) agonist requirements for symptom management were significantly reduced from baseline in these asthma patients when treated with the 5 mg/day desloratadine regimen as compared with placebo.	desloratadine	162-175	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	13-19
11295678-2	2001	In vitro studies have shown that desloratadine inhibits the release or generation of multiple inflammatory mediators, including IL-4, IL-6, IL-8, IL-13, PGD(2), leukotriene C(4), tryptase, histamine, and the TNF-alpha-induced chemokine RANTES.	desloratadine	33-46	interleukin 4	Homo sapiens	128-132
11295678-2	2001	In vitro studies have shown that desloratadine inhibits the release or generation of multiple inflammatory mediators, including IL-4, IL-6, IL-8, IL-13, PGD(2), leukotriene C(4), tryptase, histamine, and the TNF-alpha-induced chemokine RANTES.	desloratadine	33-46	interleukin 6	Homo sapiens	134-138
11295678-2	2001	In vitro studies have shown that desloratadine inhibits the release or generation of multiple inflammatory mediators, including IL-4, IL-6, IL-8, IL-13, PGD(2), leukotriene C(4), tryptase, histamine, and the TNF-alpha-induced chemokine RANTES.	desloratadine	33-46	C-X-C motif chemokine ligand 8	Homo sapiens	140-144
11295678-2	2001	In vitro studies have shown that desloratadine inhibits the release or generation of multiple inflammatory mediators, including IL-4, IL-6, IL-8, IL-13, PGD(2), leukotriene C(4), tryptase, histamine, and the TNF-alpha-induced chemokine RANTES.	desloratadine	33-46	interleukin 13	Homo sapiens	146-151
11295678-2	2001	In vitro studies have shown that desloratadine inhibits the release or generation of multiple inflammatory mediators, including IL-4, IL-6, IL-8, IL-13, PGD(2), leukotriene C(4), tryptase, histamine, and the TNF-alpha-induced chemokine RANTES.	desloratadine	33-46	tumor necrosis factor	Homo sapiens	208-217
11295678-3	2001	Desloratadine also inhibits the induction of cell adhesion molecules, plateletactivating factor-induced eosinophil chemotaxis, TNF-alpha-induced eosinophil adhesion, and spontaneous and phorbol myristate acetate-induced superoxide generation in vitro.	desloratadine	0-13	tumor necrosis factor	Homo sapiens	127-136
11295678-2	2001	In vitro studies have shown that desloratadine inhibits the release or generation of multiple inflammatory mediators, including IL-4, IL-6, IL-8, IL-13, PGD(2), leukotriene C(4), tryptase, histamine, and the TNF-alpha-induced chemokine RANTES.	desloratadine	33-46	C-C motif chemokine ligand 5	Homo sapiens	236-242
11243501-5	2001	The novel, nonsedating, histamine H1-receptor antagonist, desloratadine, which exerts various favorable effects on the allergic cascade, significantly decreased SAR symptoms (e.g., nasal congestion) and diminished daily beta2-agonist use and improved asthma symptoms, while maintaining pulmonary function, in patients with SAR-asthma who were treated with once-daily desloratadine regimens.	desloratadine	58-71	histamine receptor H1	Homo sapiens	24-45
11243501-5	2001	The novel, nonsedating, histamine H1-receptor antagonist, desloratadine, which exerts various favorable effects on the allergic cascade, significantly decreased SAR symptoms (e.g., nasal congestion) and diminished daily beta2-agonist use and improved asthma symptoms, while maintaining pulmonary function, in patients with SAR-asthma who were treated with once-daily desloratadine regimens.	desloratadine	58-71	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	220-225
11243501-5	2001	The novel, nonsedating, histamine H1-receptor antagonist, desloratadine, which exerts various favorable effects on the allergic cascade, significantly decreased SAR symptoms (e.g., nasal congestion) and diminished daily beta2-agonist use and improved asthma symptoms, while maintaining pulmonary function, in patients with SAR-asthma who were treated with once-daily desloratadine regimens.	desloratadine	367-380	histamine receptor H1	Homo sapiens	24-45
10858871-0	2000	Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist.	desloratadine	28-41	histamine receptor H 1	Rattus norvegicus	71-92
11080746-6	2000	Desloratadine, a new selective histamine H(1)-receptor antagonist with potent antihistaminic and anti-inflammatory activity, is introduced and its potential for treating the systemic aspects of allergic disease is discussed.	desloratadine	0-13	histamine receptor H1	Homo sapiens	31-54
10858871-2	2000	Desloratadine (descarboethoxyloratadine, CAS 100643-71-8) is a selective histamine H1 antagonist that exhibits qualitatively similar pharmacodynamic activity to its parent, loratadine (CAS 79794-75-5), but is 2.5-4 times more potent orally.	desloratadine	0-13	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	41-44
10858871-2	2000	Desloratadine (descarboethoxyloratadine, CAS 100643-71-8) is a selective histamine H1 antagonist that exhibits qualitatively similar pharmacodynamic activity to its parent, loratadine (CAS 79794-75-5), but is 2.5-4 times more potent orally.	desloratadine	0-13	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	185-188
9179431-7	1997	Loratadine (3 x 10(-6)-10(-4)M) and des-loratadine also inhibited (10-40%) histamine, LTC4, and PGD2 release from purified HLMC (16-68%) activated by anti-Fc epsilon RI.	desloratadine	36-50	prostaglandin D2 synthase	Homo sapiens	96-100
10800633-0	2000	Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist.	desloratadine	28-41	histamine H1 receptor	Cavia porcellus	71-92
10800633-2	2000	Desloratadine (descarboethoxyloratadine, CAS 100643-71-8) is an active metabolite of loratadine (CAS 79794-75-5) that exhibits qualitatively similar pharmacodynamic activity with a relative oral potency in animals 2.5-4 times greater than loratadine.	desloratadine	0-13	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	41-44
10800633-2	2000	Desloratadine (descarboethoxyloratadine, CAS 100643-71-8) is an active metabolite of loratadine (CAS 79794-75-5) that exhibits qualitatively similar pharmacodynamic activity with a relative oral potency in animals 2.5-4 times greater than loratadine.	desloratadine	0-13	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	97-100
10800633-2	2000	Desloratadine (descarboethoxyloratadine, CAS 100643-71-8) is an active metabolite of loratadine (CAS 79794-75-5) that exhibits qualitatively similar pharmacodynamic activity with a relative oral potency in animals 2.5-4 times greater than loratadine.	desloratadine	15-39	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	41-44
10800633-2	2000	Desloratadine (descarboethoxyloratadine, CAS 100643-71-8) is an active metabolite of loratadine (CAS 79794-75-5) that exhibits qualitatively similar pharmacodynamic activity with a relative oral potency in animals 2.5-4 times greater than loratadine.	desloratadine	15-39	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	97-100
9384491-0	1997	Effect of descarboethoxyloratadine, the major metabolite of loratadine, on the human cardiac potassium channel Kv1.5.	desloratadine	10-34	potassium voltage-gated channel subfamily A member 5	Homo sapiens	111-116
9384491-2	1997	DCL (1-100 microM) inhibited hKv1.5 current in a concentration-dependent manner with an apparent affinity constant of 12.5+/-1.2 microM.	desloratadine	0-3	potassium voltage-gated channel subfamily A member 5	Homo sapiens	29-35
9384491-6	1997	The present results demonstrated that DCL blocked hKv1.5 channels in a concentration-, voltage-, and time-dependent manner.	desloratadine	38-41	potassium voltage-gated channel subfamily A member 5	Homo sapiens	50-56
9179431-7	1997	Loratadine (3 x 10(-6)-10(-4)M) and des-loratadine also inhibited (10-40%) histamine, LTC4, and PGD2 release from purified HLMC (16-68%) activated by anti-Fc epsilon RI.	desloratadine	36-50	Fc epsilon receptor Ia	Homo sapiens	155-168
9179431-8	1997	Loratadine (3 x 10(-6)-10(-4)M) and des-loratadine caused concentration-dependent inhibition (10-40%) of histamine, tryptase, LTC4, and PGD2 release from purified HSMC (24-72%) immunologically challenged with anti-Fc epsilon RI.	desloratadine	36-50	prostaglandin D2 synthase	Homo sapiens	136-140
9179431-8	1997	Loratadine (3 x 10(-6)-10(-4)M) and des-loratadine caused concentration-dependent inhibition (10-40%) of histamine, tryptase, LTC4, and PGD2 release from purified HSMC (24-72%) immunologically challenged with anti-Fc epsilon RI.	desloratadine	36-50	Fc epsilon receptor Ia	Homo sapiens	214-227
7677235-0	1995	Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells.	desloratadine	38-62	intercellular adhesion molecule 1	Homo sapiens	80-86
8615885-1	1996	Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.	desloratadine	13-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
8615885-1	1996	Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.	desloratadine	13-37	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	52-58
8615885-7	1996	With the addition of ketoconazole (CYP3A4 inhibitor) to the incubation mixtures, the residual rate of formation of DCL correlated (r2 = 0.81) with that for dextromethorphan O-demethylation, a CYP2D6 reaction.	desloratadine	115-118	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	35-41
8615885-7	1996	With the addition of ketoconazole (CYP3A4 inhibitor) to the incubation mixtures, the residual rate of formation of DCL correlated (r2 = 0.81) with that for dextromethorphan O-demethylation, a CYP2D6 reaction.	desloratadine	115-118	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	192-198
8615885-8	1996	Rabbit polyclonal antibodies raised against the rat CYP3A1 enzyme (5 mg IgG/nmol P450) and troleandomycin (0.5 microM), a specific inhibitor of CYP3A4, decreased the formation of DCL by 53 and 75%, respectively, when added to 1.42 microM loratadine microsomal incubations.	desloratadine	179-182	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	52-58
8615885-8	1996	Rabbit polyclonal antibodies raised against the rat CYP3A1 enzyme (5 mg IgG/nmol P450) and troleandomycin (0.5 microM), a specific inhibitor of CYP3A4, decreased the formation of DCL by 53 and 75%, respectively, when added to 1.42 microM loratadine microsomal incubations.	desloratadine	179-182	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	144-150
8615885-9	1996	Quinidine (5 microm), a CYP2D6 inhibitor, inhibited the formation of DCL approximately 20% when added to microsomal incubations of loratadine at concentrations of 7-35 microM.	desloratadine	69-72	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	24-30
8615885-10	1996	Incubation of loratadine with cDNA-expressed CYP3A4 and CYP2D6 microsomes catalysed the formation of DCL with formation rates of 135 and 633 pmol/min/nmol P450, respectively.	desloratadine	101-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
8615885-10	1996	Incubation of loratadine with cDNA-expressed CYP3A4 and CYP2D6 microsomes catalysed the formation of DCL with formation rates of 135 and 633 pmol/min/nmol P450, respectively.	desloratadine	101-104	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	56-62
8615885-11	1996	The results indicated that loratadine was metabolized to DCL primarily by the CYP3A4 and CYP2D6 enzymes in human liver microsomes.	desloratadine	57-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	78-84
8615885-11	1996	The results indicated that loratadine was metabolized to DCL primarily by the CYP3A4 and CYP2D6 enzymes in human liver microsomes.	desloratadine	57-60	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	89-95
8615885-12	1996	In the presence of a CYP3A4 inhibitor, loratadine was metabolized to DCL by the CYP2D6 enzyme.	desloratadine	69-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-27
8615885-12	1996	In the presence of a CYP3A4 inhibitor, loratadine was metabolized to DCL by the CYP2D6 enzyme.	desloratadine	69-72	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	80-86
32970826-8	2021	Recent studies have shown clinically significant increases in exposure to CYP2C8 substrates (repaglinide, dasabuvir, desloratidine) and a CYP2B6 substrate (s-sibutramine) following co-administration with clopidogrel, indicating that therapeutic strategies with clopidogrel should avoid these drugs.	desloratadine	117-130	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	74-80
34517748-9	2021	DISCUSSION AND CONCLUSION: The combination of desloratadine and compound glycyrrhizin is a promising treatment for CU and is associated with decreased serum IgE level and improved proportions of CD4+ T and CD8+ T cells.	desloratadine	46-59	CD4 molecule	Homo sapiens	195-198
34517748-9	2021	DISCUSSION AND CONCLUSION: The combination of desloratadine and compound glycyrrhizin is a promising treatment for CU and is associated with decreased serum IgE level and improved proportions of CD4+ T and CD8+ T cells.	desloratadine	46-59	CD8a molecule	Homo sapiens	206-209
34681275-6	2021	Using virtual drug screening and molecular docking analyses, we identified FDA-approved compounds (conivaptan, bexarotene, and desloratadine) that were interacting with HMOX1 and PRKCA at even stronger binding affinities than 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethenone and ellagic acid as known inhibitors of HMOX1 and PRKCA, respectively.	desloratadine	127-140	heme oxygenase 1	Homo sapiens	169-174
34681275-6	2021	Using virtual drug screening and molecular docking analyses, we identified FDA-approved compounds (conivaptan, bexarotene, and desloratadine) that were interacting with HMOX1 and PRKCA at even stronger binding affinities than 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethenone and ellagic acid as known inhibitors of HMOX1 and PRKCA, respectively.	desloratadine	127-140	protein kinase C alpha	Homo sapiens	179-184
34681275-6	2021	Using virtual drug screening and molecular docking analyses, we identified FDA-approved compounds (conivaptan, bexarotene, and desloratadine) that were interacting with HMOX1 and PRKCA at even stronger binding affinities than 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethenone and ellagic acid as known inhibitors of HMOX1 and PRKCA, respectively.	desloratadine	127-140	heme oxygenase 1	Homo sapiens	314-319
34681275-6	2021	Using virtual drug screening and molecular docking analyses, we identified FDA-approved compounds (conivaptan, bexarotene, and desloratadine) that were interacting with HMOX1 and PRKCA at even stronger binding affinities than 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethenone and ellagic acid as known inhibitors of HMOX1 and PRKCA, respectively.	desloratadine	127-140	protein kinase C alpha	Homo sapiens	324-329
34502144-8	2021	AuNP@PLA in combination with desloratadine was proven to induce PHD-2 silencing in fibroblasts, allowing upregulation of pro-angiogenic pathways.	desloratadine	29-42	egl-9 family hypoxia inducible factor 1	Homo sapiens	64-69
35096719-7	2021	The effective rate of treatment of OAB in patients complicated with allergies and taking desloratadine was 90.14%, which was significantly higher than in patients who were not taking desloratadine, and blood IgE level was a risk factor of ineffective treatment with desloratadine.	desloratadine	266-279	immunoglobulin heavy constant epsilon	Homo sapiens	208-211
33609497-4	2021	In this study, in vitro severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike pseudotyped viral infection experiments indicated that histamine H1 antagonists loratadine (LOR) and desloratadine (DES) could prevent entry of the pseudotyped virus into ACE2-overexpressing HEK293T cells and showed that DES was more effective.	desloratadine	192-205	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	85-90
33609497-4	2021	In this study, in vitro severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike pseudotyped viral infection experiments indicated that histamine H1 antagonists loratadine (LOR) and desloratadine (DES) could prevent entry of the pseudotyped virus into ACE2-overexpressing HEK293T cells and showed that DES was more effective.	desloratadine	192-205	angiotensin converting enzyme 2	Homo sapiens	262-266
33609497-4	2021	In this study, in vitro severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike pseudotyped viral infection experiments indicated that histamine H1 antagonists loratadine (LOR) and desloratadine (DES) could prevent entry of the pseudotyped virus into ACE2-overexpressing HEK293T cells and showed that DES was more effective.	desloratadine	207-210	angiotensin converting enzyme 2	Homo sapiens	262-266
33609497-5	2021	Further binding experiments using cell membrane chromatography and surface plasmon resonance demonstrated that both antagonists could bind to ACE2 and that the binding affinity of DES was much stronger than that of LOR.	desloratadine	180-183	angiotensin converting enzyme 2	Homo sapiens	142-146
33609497-6	2021	Molecular docking results elucidated that LOR and DES could bind to ACE2 on the interface of the SARS-CoV-2-binding area.	desloratadine	50-53	angiotensin converting enzyme 2	Homo sapiens	68-72
33609497-8	2021	To our knowledge, this study is the first to demonstrate the inhibitory effect of LOR and DES on SARS-CoV-2 spike pseudotyped virus viropexis by blocking spike protein-ACE2 interaction.	desloratadine	90-93	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	108-113
33609497-8	2021	To our knowledge, this study is the first to demonstrate the inhibitory effect of LOR and DES on SARS-CoV-2 spike pseudotyped virus viropexis by blocking spike protein-ACE2 interaction.	desloratadine	90-93	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	154-159
33609497-8	2021	To our knowledge, this study is the first to demonstrate the inhibitory effect of LOR and DES on SARS-CoV-2 spike pseudotyped virus viropexis by blocking spike protein-ACE2 interaction.	desloratadine	90-93	angiotensin converting enzyme 2	Homo sapiens	168-172
33550204-1	2021	BACKGROUND: We have previously shown an association with substantially improved survival in breast cancer and melanoma for desloratadine and loratadine users, and set out to find whether an improved survival can be seen in tumors with and without a known response to immune checkpoint therapy, such as anti-CTLA-4 or anti-PD-1.	desloratadine	123-136	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	307-313
33726554-8	2021	RESULTS: The treatment with desloratadine alone down-regulated the CD86 expression, and decreased the production of Th2 cytokines, but had no impact on the expression of MHC-II, CD80 and OX40L.	desloratadine	28-41	CD86 molecule	Rattus norvegicus	67-71
33369003-4	2021	Here, we discovered that clinically first-line antiallergic drug desloratadine (DLT) functioned as a selective antagonist of 5HT2A R and efficiently ameliorated pathology of APP/PS1 mice.	desloratadine	65-78	presenilin 1	Mus musculus	178-181
33369003-0	2021	Antiallergic drug desloratadine as a selective antagonist of 5HT2A receptor ameliorates pathology of Alzheimer"s disease model mice by improving microglial dysfunction.	desloratadine	18-31	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	61-75
33369003-4	2021	Here, we discovered that clinically first-line antiallergic drug desloratadine (DLT) functioned as a selective antagonist of 5HT2A R and efficiently ameliorated pathology of APP/PS1 mice.	desloratadine	65-78	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	125-132
31406237-0	2020	Human H1 receptor (HRH1) gene polymorphism is associated with the severity of side effects after desloratadine treatment in Chinese patients with chronic spontaneous uticaria.	desloratadine	97-110	histamine receptor H1	Homo sapiens	19-23
33100209-1	2021	BACKGROUND: For the first time, the inhibitory effects on human salivary alpha-amylase activity of the antiinflammatory drugs: indomethacin, diclofenac sodium, ketoprofen, diclofenac potassium, diclofenac, triamcinolone acetonide and the antihistamines drugs: levocetirizine dihydrochloride, desloratadine, cycloheptadine hydrochloride has been investigated to confirm the other properties of these drugs.	desloratadine	292-305	amylase alpha 1A	Homo sapiens	64-86
32076842-0	2020	Desloratadine Ameliorates Olfactory Disorder and Suppresses AMPA Receptor GluA1 Expression in Allergic Rhinitis Rat.	desloratadine	0-13	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	74-79
32076842-7	2020	Desloratadine treatment alleviated AR symptoms, decreased serum level of OVA-specific IgE and IL-17 in AR rats.	desloratadine	0-13	interleukin 17A	Rattus norvegicus	94-99
32076842-8	2020	Desloratadine decreased IL-4, IL-5, and IL-13 expression in nasal mucosa of AR rats.	desloratadine	0-13	interleukin 4	Rattus norvegicus	24-28
32076842-8	2020	Desloratadine decreased IL-4, IL-5, and IL-13 expression in nasal mucosa of AR rats.	desloratadine	0-13	interleukin 5	Rattus norvegicus	30-34
32076842-8	2020	Desloratadine decreased IL-4, IL-5, and IL-13 expression in nasal mucosa of AR rats.	desloratadine	0-13	interleukin 13	Rattus norvegicus	40-45
32076842-9	2020	Desloratadine ameliorated olfactory dysfunction in AR rats and decreased GluR1 expression in AR rats.	desloratadine	0-13	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	73-78
32043642-0	2021	Desloratadine inhibits heterotopic ossification by suppression of BMP2-Smad1/5/8 signaling.	desloratadine	0-13	bone morphogenetic protein 2	Mus musculus	66-70
32043642-0	2021	Desloratadine inhibits heterotopic ossification by suppression of BMP2-Smad1/5/8 signaling.	desloratadine	0-13	SMAD family member 1	Mus musculus	71-78
32043642-10	2021	Desloratadine suppressed phosphorylation of Smad1/5/8 induced by BMP2 in PDGFRalpha+ cells.	desloratadine	0-13	SMAD family member 1	Mus musculus	44-51
32043642-10	2021	Desloratadine suppressed phosphorylation of Smad1/5/8 induced by BMP2 in PDGFRalpha+ cells.	desloratadine	0-13	bone morphogenetic protein 2	Mus musculus	65-69
31406237-3	2020	Herein, we evaluated the association between HRH1 gene rs901865 polymorphism and the severity of sedation side effect following desloratadine therapy in patients with CSU.	desloratadine	128-141	histamine receptor H1	Homo sapiens	45-49
31406237-7	2020	These results provide evidence that the HRH1 rs901865 G/G polymorphism is associated with severe sedation side effect after desloratadine treatment.	desloratadine	124-137	histamine receptor H1	Homo sapiens	40-44
31406237-8	2020	Thus, the HRH1 rs901865 allele may potentially be used as a biomarker for predicting the severity of sedation side effect in patients suffering from CSU and treated with desloratadine.	desloratadine	170-183	histamine receptor H1	Homo sapiens	10-14
33109037-2	2020	CYP2C8 and UGT2B10 are metabolic enzymes, which may be involved in the metabolism of desloratadine.	desloratadine	85-98	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	0-6
33109037-2	2020	CYP2C8 and UGT2B10 are metabolic enzymes, which may be involved in the metabolism of desloratadine.	desloratadine	85-98	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	11-18
30863716-2	2019	For alleviation of allergic symptoms, H1R antagonists are therapeutic drugs; of which the most frequently prescribed are second generation drugs, such as; Cetirizine, Loratadine, Hydroxyzine, Desloratadine, Bepotastine, Acrivastine and Rupatadine.	desloratadine	192-205	histamine receptor H1	Homo sapiens	38-41
32406319-1	2020	Desloratadine, a potent antagonist for human histamine H1 receptor, has been revealed to exhibit antihistaminic activity and anti-inflammatory activity.	desloratadine	0-13	histamine receptor H1	Homo sapiens	45-66
32406319-6	2020	Desloratadine promoted cell apoptosis via modulating the expression of Bcl-2, Bax, cleaved caspase 3, and cleaved caspase 9 in EJ and SW780 cells.	desloratadine	0-13	BCL2 apoptosis regulator	Homo sapiens	71-76
32406319-6	2020	Desloratadine promoted cell apoptosis via modulating the expression of Bcl-2, Bax, cleaved caspase 3, and cleaved caspase 9 in EJ and SW780 cells.	desloratadine	0-13	BCL2 associated X, apoptosis regulator	Homo sapiens	78-81
32406319-6	2020	Desloratadine promoted cell apoptosis via modulating the expression of Bcl-2, Bax, cleaved caspase 3, and cleaved caspase 9 in EJ and SW780 cells.	desloratadine	0-13	caspase 9	Homo sapiens	114-123
32406319-7	2020	Western blot resulted showed that desloratadine also impaired the expression of autophagy-related proteins, such as Beclin 1, P62, and LC3I/II in EJ and SW780 cells; while autophagy inhibitor LY294002 reversed the effects of desloratadine on these proteins.	desloratadine	34-47	beclin 1	Homo sapiens	116-124
32406319-7	2020	Western blot resulted showed that desloratadine also impaired the expression of autophagy-related proteins, such as Beclin 1, P62, and LC3I/II in EJ and SW780 cells; while autophagy inhibitor LY294002 reversed the effects of desloratadine on these proteins.	desloratadine	34-47	nucleoporin 62	Homo sapiens	126-129
32406319-9	2020	Furthermore, we illustrated that desloratadine downregulated the expression of N-cadherin, Vimentin, Snail1, and Snail2, while upregulated the expression of E-cadherin in EJ and SW780 cells in vitro.	desloratadine	33-46	cadherin 2	Homo sapiens	79-89
32406319-9	2020	Furthermore, we illustrated that desloratadine downregulated the expression of N-cadherin, Vimentin, Snail1, and Snail2, while upregulated the expression of E-cadherin in EJ and SW780 cells in vitro.	desloratadine	33-46	vimentin	Homo sapiens	91-99
32406319-9	2020	Furthermore, we illustrated that desloratadine downregulated the expression of N-cadherin, Vimentin, Snail1, and Snail2, while upregulated the expression of E-cadherin in EJ and SW780 cells in vitro.	desloratadine	33-46	snail family transcriptional repressor 1	Homo sapiens	101-107
32406319-9	2020	Furthermore, we illustrated that desloratadine downregulated the expression of N-cadherin, Vimentin, Snail1, and Snail2, while upregulated the expression of E-cadherin in EJ and SW780 cells in vitro.	desloratadine	33-46	snail family transcriptional repressor 2	Homo sapiens	113-119
32406319-9	2020	Furthermore, we illustrated that desloratadine downregulated the expression of N-cadherin, Vimentin, Snail1, and Snail2, while upregulated the expression of E-cadherin in EJ and SW780 cells in vitro.	desloratadine	33-46	cadherin 1	Homo sapiens	157-167
32406319-10	2020	The level of interleukin 6 was reduced in desloratadine-treated cells, while upregulation of interleukin 6 significantly abolished the anticancer activity of desloratadine in cell invasion and Bcl-2, Bax, Beclin1, LC3-I/II, N-cadherin, and E-cadherin expression in EJ cells.	desloratadine	42-55	interleukin 6	Homo sapiens	13-26
32406319-10	2020	The level of interleukin 6 was reduced in desloratadine-treated cells, while upregulation of interleukin 6 significantly abolished the anticancer activity of desloratadine in cell invasion and Bcl-2, Bax, Beclin1, LC3-I/II, N-cadherin, and E-cadherin expression in EJ cells.	desloratadine	42-55	cadherin 2	Homo sapiens	224-234
32406319-10	2020	The level of interleukin 6 was reduced in desloratadine-treated cells, while upregulation of interleukin 6 significantly abolished the anticancer activity of desloratadine in cell invasion and Bcl-2, Bax, Beclin1, LC3-I/II, N-cadherin, and E-cadherin expression in EJ cells.	desloratadine	42-55	cadherin 1	Homo sapiens	240-250
32406319-10	2020	The level of interleukin 6 was reduced in desloratadine-treated cells, while upregulation of interleukin 6 significantly abolished the anticancer activity of desloratadine in cell invasion and Bcl-2, Bax, Beclin1, LC3-I/II, N-cadherin, and E-cadherin expression in EJ cells.	desloratadine	158-171	interleukin 6	Homo sapiens	93-106
32406319-10	2020	The level of interleukin 6 was reduced in desloratadine-treated cells, while upregulation of interleukin 6 significantly abolished the anticancer activity of desloratadine in cell invasion and Bcl-2, Bax, Beclin1, LC3-I/II, N-cadherin, and E-cadherin expression in EJ cells.	desloratadine	158-171	cadherin 2	Homo sapiens	224-234
32406319-10	2020	The level of interleukin 6 was reduced in desloratadine-treated cells, while upregulation of interleukin 6 significantly abolished the anticancer activity of desloratadine in cell invasion and Bcl-2, Bax, Beclin1, LC3-I/II, N-cadherin, and E-cadherin expression in EJ cells.	desloratadine	158-171	cadherin 1	Homo sapiens	240-250
32406319-11	2020	Taken together, our data suggest a potential anticancer activity of desloratadine on cell growth and invasion for bladder cancer, which may be mediated by diminishing the epithelial-to-mesenchymal transition and interleukin 6.	desloratadine	68-81	interleukin 6	Homo sapiens	212-225
31274307-0	2019	Route to Prolonged Residence Time at the Histamine H1 Receptor: Growing from Desloratadine to Rupatadine.	desloratadine	77-90	histamine receptor H1	Homo sapiens	41-62
31274307-2	2019	We show that both rupatadine (1) and desloratadine (2) have a long residence time at the histamine H1 receptor (H1R).	desloratadine	37-50	histamine receptor H1	Homo sapiens	89-110
31274307-2	2019	We show that both rupatadine (1) and desloratadine (2) have a long residence time at the histamine H1 receptor (H1R).	desloratadine	37-50	histamine receptor H1	Homo sapiens	112-115
31274307-5	2019	Methylene-linked cycloaliphatic or beta-branched substitutions of desloratadine increase the residence time at the H1R, conveying a longer duration of receptor antagonism.	desloratadine	66-79	histamine receptor H1	Homo sapiens	115-118
30630815-1	2019	A recent in vitro study suggested that CYP2C8 is essential in the metabolism of desloratadine, an H1 receptor antagonist.	desloratadine	80-93	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	39-45
30630815-2	2019	If the proposed biotransformation mechanism takes place in vivo in humans, desloratadine could serve as a selective CYP2C8 probe substrate in drug-drug interaction studies.	desloratadine	75-88	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	116-122
30630815-4	2019	We conducted a randomized crossover study in 11 healthy subjects to characterize the involvement of CYP2C8 in desloratadine metabolism and to compare the CYP2C8 inhibitory strength of clopidogrel (300 and 75 mg on two following days) with that of gemfibrozil (600 mg BID for 5 days).	desloratadine	110-123	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	100-106
30630815-9	2019	Our results confirm that CYP2C8 plays a critical role in the formation of 3-hydroxydesloratadine in humans, making desloratadine a potential CYP2C8 probe substrate.	desloratadine	83-96	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	25-31
30630815-9	2019	Our results confirm that CYP2C8 plays a critical role in the formation of 3-hydroxydesloratadine in humans, making desloratadine a potential CYP2C8 probe substrate.	desloratadine	83-96	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	141-147
30084285-5	2018	RESULTS: Forty-nine unique case reports of desloratadine associated with depression or depressed mood were detected in the WHO global ADR database.	desloratadine	43-56	aldo-keto reductase family 1 member B	Homo sapiens	134-137
29143966-3	2018	Here we present the results of an in vitro study of potential drug-drug interactions at the level of the hERG channel for the combination of up to three compounds: loratadine, desloratadine and ketoconazole.	desloratadine	176-189	ETS transcription factor ERG	Homo sapiens	105-109
27864023-0	2017	Association of ORAI1 gene polymorphisms with chronic spontaneous urticaria and the efficacy of the nonsedating H1 antihistamine desloratadine.	desloratadine	128-141	ORAI calcium release-activated calcium modulator 1	Homo sapiens	15-20
28351163-14	2017	CONCLUSIONS: Desloratadine exerted anti-inflammatory and antioxidant effects on CSU patients revealed by CRP.	desloratadine	13-26	C-reactive protein	Homo sapiens	105-108
27758758-11	2017	Rupatadine (1-10 microM), levocetirizine (1-10 microM), and desloratadine (10 microM) inhibited PAF-induced histamine release.	desloratadine	60-73	PCNA clamp associated factor	Homo sapiens	96-99
26135009-0	2015	Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor.	desloratadine	46-59	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	196-203
26348733-7	2015	In addition, cynomolgus monkey CYP2C19 formed the same loratadine metabolite as human CYP2C19, descarboethoxyloratadine.	desloratadine	95-119	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	31-38
26348733-7	2015	In addition, cynomolgus monkey CYP2C19 formed the same loratadine metabolite as human CYP2C19, descarboethoxyloratadine.	desloratadine	95-119	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	86-93
26135009-0	2015	Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor.	desloratadine	156-169	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	196-203
26135009-2	2015	Previously we reported that the formation of 3-hydroxydesloratadine, the major human metabolite of desloratadine, involves three sequential reactions, namely N-glucuronidation by UGT2B10 followed by 3-hydroxylation by CYP2C8 followed by deconjugation (rapid, nonenzymatic hydrolysis of the N-glucuronide).	desloratadine	54-67	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	179-186
26135009-2	2015	Previously we reported that the formation of 3-hydroxydesloratadine, the major human metabolite of desloratadine, involves three sequential reactions, namely N-glucuronidation by UGT2B10 followed by 3-hydroxylation by CYP2C8 followed by deconjugation (rapid, nonenzymatic hydrolysis of the N-glucuronide).	desloratadine	54-67	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	218-224
26135009-3	2015	In this study we assessed the perpetrator potential of desloratadine based on in vitro studies of its inhibitory effects on cytochrome P450 and UDP-glucuronosyltransferase (UGT) enzymes in human liver microsomes (HLM).	desloratadine	55-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-139
26135009-3	2015	In this study we assessed the perpetrator potential of desloratadine based on in vitro studies of its inhibitory effects on cytochrome P450 and UDP-glucuronosyltransferase (UGT) enzymes in human liver microsomes (HLM).	desloratadine	55-68	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	144-171
26135009-3	2015	In this study we assessed the perpetrator potential of desloratadine based on in vitro studies of its inhibitory effects on cytochrome P450 and UDP-glucuronosyltransferase (UGT) enzymes in human liver microsomes (HLM).	desloratadine	55-68	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	173-176
26135009-4	2015	Desloratadine (10 microM) caused no inhibition (<15%) of CYP1A2, CYP2C8, CYP2C9, or CYP2C19 and weak inhibition (32-48%) of CYP2B6, CYP2D6, and CYP3A4/5.	desloratadine	0-13	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	127-133
26135009-4	2015	Desloratadine (10 microM) caused no inhibition (<15%) of CYP1A2, CYP2C8, CYP2C9, or CYP2C19 and weak inhibition (32-48%) of CYP2B6, CYP2D6, and CYP3A4/5.	desloratadine	0-13	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	135-141
26135009-4	2015	Desloratadine (10 microM) caused no inhibition (<15%) of CYP1A2, CYP2C8, CYP2C9, or CYP2C19 and weak inhibition (32-48%) of CYP2B6, CYP2D6, and CYP3A4/5.	desloratadine	0-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	147-153
26135009-6	2015	Assessment of UGT inhibition identified desloratadine as a potent and relatively selective competitive inhibitor of UGT2B10 (Ki value of 1.3 muM).	desloratadine	40-53	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	14-17
26135009-6	2015	Assessment of UGT inhibition identified desloratadine as a potent and relatively selective competitive inhibitor of UGT2B10 (Ki value of 1.3 muM).	desloratadine	40-53	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	116-123
26135009-7	2015	Chemical inhibition of UGT enzymes in HLM demonstrated that nicotine (UGT2B10 inhibitor) but not hecogenin (UGT1A4 inhibitor) completely inhibited the conversion of desloratadine (1 microM) to 3-hydroxydesloratadine in HLM fortified with both NADPH and UDP-glucuronic acid.	desloratadine	165-178	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	23-26
26135009-7	2015	Chemical inhibition of UGT enzymes in HLM demonstrated that nicotine (UGT2B10 inhibitor) but not hecogenin (UGT1A4 inhibitor) completely inhibited the conversion of desloratadine (1 microM) to 3-hydroxydesloratadine in HLM fortified with both NADPH and UDP-glucuronic acid.	desloratadine	165-178	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	70-77
24566331-0	2014	Synthesis and biological evaluation of substituted desloratadines as potent arginine vasopressin V2 receptor antagonists.	desloratadine	51-65	arginine vasopressin receptor 2	Homo sapiens	85-108
25595597-0	2015	A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement.	desloratadine	58-71	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	88-94
25595597-0	2015	A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement.	desloratadine	58-71	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	141-173
25595597-7	2015	Assessment of desloratadine, amodiaquine, and paclitaxel metabolism by a panel of individual CHHs demonstrated that CYP2C8 marker activity robustly correlated with 3-hydroxydesloratadine formation (r(2) of 0.70-0.90).	desloratadine	14-27	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	116-122
25595597-9	2015	Overall, our results demonstrate for the first time that desloratadine glucuronidation by UGT2B10 followed by CYP2C8 oxidation and a deconjugation event are responsible for the formation of 3-hydroxydesloratadine.	desloratadine	57-70	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	90-97
23657985-5	2013	Among the eight drugs studied, prednisone, desloratadine, and azelastine exhibited the highest binding affinity (K(d) = 1.65, 2.05, and 8.47 muM, respectively) toward DNA photolyase.	desloratadine	43-56	latexin	Homo sapiens	141-144
22994340-8	2012	From the data reviewed in this article, especially the direct comparative data of desloratadine and levocetirizine in weal and flare studies and CSU, weal and flare response would appear to be the best indicator we have of effectiveness of H(1)-antihistamines in clinical practice.	desloratadine	82-95	H1.5 linker histone, cluster member	Homo sapiens	240-244
23362870-0	2013	The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines.	desloratadine	34-47	signal transducer and activator of transcription 3	Homo sapiens	56-61
23362870-0	2013	The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines.	desloratadine	34-47	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	66-71
23362870-4	2013	The two antihistamines clemastine and desloratadine, currently used for symptom alleviation in allergy, induced potent reduction of the activities of the constitutively active transcription factors c-Myc, STAT3, STAT5a and STAT5b in mycosis fungoides and Sezary syndrome cell lines.	desloratadine	38-51	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	198-203
23362870-4	2013	The two antihistamines clemastine and desloratadine, currently used for symptom alleviation in allergy, induced potent reduction of the activities of the constitutively active transcription factors c-Myc, STAT3, STAT5a and STAT5b in mycosis fungoides and Sezary syndrome cell lines.	desloratadine	38-51	signal transducer and activator of transcription 3	Homo sapiens	205-210
23362870-4	2013	The two antihistamines clemastine and desloratadine, currently used for symptom alleviation in allergy, induced potent reduction of the activities of the constitutively active transcription factors c-Myc, STAT3, STAT5a and STAT5b in mycosis fungoides and Sezary syndrome cell lines.	desloratadine	38-51	signal transducer and activator of transcription 5A	Homo sapiens	212-218
23362870-4	2013	The two antihistamines clemastine and desloratadine, currently used for symptom alleviation in allergy, induced potent reduction of the activities of the constitutively active transcription factors c-Myc, STAT3, STAT5a and STAT5b in mycosis fungoides and Sezary syndrome cell lines.	desloratadine	38-51	signal transducer and activator of transcription 5B	Homo sapiens	223-229
23362870-7	2013	Because both c-Myc and STAT transcription factors are highly expressed in proliferating tumours, their inhibition by clemastine, desloratadine and other inhibitors could complement established chemotherapies not only for cutaneous T-cell lymphomas but perhaps also other cancers.	desloratadine	129-142	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	13-18
21352574-8	2011	In mucosa and polyp epithelial cells, mometasone inhibited this induced secretion while desloratadine inhibited IL-6 and IL-8.	desloratadine	88-101	interleukin 6	Homo sapiens	112-116
23268479-0	2012	Review of Desloratadine Data Using the ARIA Guidelines.	desloratadine	10-23	endothelial cell surface expressed chemotaxis and apoptosis regulator	Homo sapiens	39-43
23282891-0	2012	Review of Desloratadine Data Using the ARIA Guidelines.	desloratadine	10-23	endothelial cell surface expressed chemotaxis and apoptosis regulator	Homo sapiens	39-43
21352574-8	2011	In mucosa and polyp epithelial cells, mometasone inhibited this induced secretion while desloratadine inhibited IL-6 and IL-8.	desloratadine	88-101	C-X-C motif chemokine ligand 8	Homo sapiens	121-125
21352574-9	2011	The combination of 10(-5) M desloratadine and 10(-9) M mometasone reduced IL-6 secretion (48 +- 11%, p < 0.05) greater extent than mometasone alone (68 +- 10%) compared to control (100%).	desloratadine	28-41	interleukin 6	Homo sapiens	74-78
21696712-0	2011	Combination treatment of mice with CRx-153 (nortriptyline and desloratadine) decreases the severity of experimental autoimmune encephalomyelitis.	desloratadine	62-75	cone-rod homeobox	Mus musculus	35-38
21696712-4	2011	The findings show that combination treatment with desloratadine and nortriptyline decreases the mean clinical score, disease relapse frequency, and number of CD4(+) T cells infiltrating into the CNS.	desloratadine	50-63	CD4 antigen	Mus musculus	158-161
21696712-7	2011	The data also show that combination treatment with desloratadine and nortriptyline inhibits the production of IFN-gamma and IL-17 produced by naive CD4(+) T cells activated in the presence of Th1 cell- and Th17 cell-promoting conditions, while increasing the level of IL-4 produced by naive CD4(+) T cells activated in the presence of Th2 cell-promoting conditions.	desloratadine	51-64	interferon gamma	Mus musculus	110-119
21696712-7	2011	The data also show that combination treatment with desloratadine and nortriptyline inhibits the production of IFN-gamma and IL-17 produced by naive CD4(+) T cells activated in the presence of Th1 cell- and Th17 cell-promoting conditions, while increasing the level of IL-4 produced by naive CD4(+) T cells activated in the presence of Th2 cell-promoting conditions.	desloratadine	51-64	interleukin 17A	Mus musculus	124-129
21696712-7	2011	The data also show that combination treatment with desloratadine and nortriptyline inhibits the production of IFN-gamma and IL-17 produced by naive CD4(+) T cells activated in the presence of Th1 cell- and Th17 cell-promoting conditions, while increasing the level of IL-4 produced by naive CD4(+) T cells activated in the presence of Th2 cell-promoting conditions.	desloratadine	51-64	CD4 antigen	Mus musculus	148-151
21696712-7	2011	The data also show that combination treatment with desloratadine and nortriptyline inhibits the production of IFN-gamma and IL-17 produced by naive CD4(+) T cells activated in the presence of Th1 cell- and Th17 cell-promoting conditions, while increasing the level of IL-4 produced by naive CD4(+) T cells activated in the presence of Th2 cell-promoting conditions.	desloratadine	51-64	interleukin 4	Mus musculus	268-272
21696712-7	2011	The data also show that combination treatment with desloratadine and nortriptyline inhibits the production of IFN-gamma and IL-17 produced by naive CD4(+) T cells activated in the presence of Th1 cell- and Th17 cell-promoting conditions, while increasing the level of IL-4 produced by naive CD4(+) T cells activated in the presence of Th2 cell-promoting conditions.	desloratadine	51-64	CD4 antigen	Mus musculus	291-294
18498541-16	2008	Mizolastine and desloratadine dose-dependently decreased tumour necrosis factor-alpha-induced production of RANTES.	desloratadine	16-29	C-C motif chemokine 5	Cavia porcellus	108-114
20493834-4	2010	The treatment with desloratadine normalized the superoxide dismutase and catalase activity as well as the malondialdehyde formation.	desloratadine	19-32	catalase	Homo sapiens	73-81
19236123-1	2009	BACKGROUND: Desloratadine is a non-sedating, long-acting histamine H(1) receptor antagonist indicated for the symptomatic relief of allergic rhinitis (AR) and chronic idiopathic urticaria in patients aged>12 years.	desloratadine	12-25	histamine receptor H1	Homo sapiens	57-80
18035184-4	2007	Desloratadine has been approved by the European Medicines Evaluation Agency for the treatment of intermittent and persistent AR, as defined by the ARIA classification.	desloratadine	0-13	endothelial cell surface expressed chemotaxis and apoptosis regulator	Homo sapiens	147-151
17906161-1	2007	Desloratadine, a nonsedating histamine H(1)-receptor antagonist, is metabolized to 3-hydroxy (3-OH) desloratadine.	desloratadine	0-13	histamine receptor H1	Homo sapiens	29-52
18035184-5	2007	OBJECTIVE: The purpose of this review was to assess data concerning desloratadine in relation to the ARIA definitions of intermittent and persistent AR.	desloratadine	68-81	endothelial cell surface expressed chemotaxis and apoptosis regulator	Homo sapiens	101-105
18035184-8	2007	RESULTS: Desloratadine has been found to be effective and well tolerated in studies in subjects with symptoms of AR analogous to/consistent with the ARIA definitions of intermittent and persistent disease.	desloratadine	9-22	endothelial cell surface expressed chemotaxis and apoptosis regulator	Homo sapiens	149-153
17298105-2	2007	Desloratadine, a second-generation histamine H(1) receptor antagonist (antihistamine), is a first-line treatment option for CIU.	desloratadine	0-13	histamine receptor H1	Homo sapiens	35-58
17362245-9	2007	Desloratadine was associated with significant reductions in total symptoms scores (SMD -1.63; 95% CI -2.75 to -0.51; P = 0.004) and total nasal symptoms score (SMD -0.66; 95% CI -0.91 to -0.42; P < 0.001), when compared with placebo.	desloratadine	0-13	small nuclear ribonucleoprotein D1 polypeptide	Homo sapiens	83-89
17577463-2	2007	Desloratadine, a once-daily selective histamine H(1)-receptor antagonist, has been reported to be efficacious in relieving symptoms of SAR in controlled clinical trials.	desloratadine	0-13	histamine receptor H1	Homo sapiens	38-61
19356011-1	2007	The possibility that non-sedating antihistamines could elicit sedation in mice due to drug-induced inhibition of brain PgP was evaluated by measuring the ability of desloratadine alone or in combination with verapamil to cause ataxia in mice.	desloratadine	165-178	phosphoglycolate phosphatase	Mus musculus	119-122
19356011-5	2007	These data suggest that inhibition of brain PgP can convert desloratadine to a sedating antihistamine in mice.	desloratadine	60-73	phosphoglycolate phosphatase	Mus musculus	44-47
16530440-0	2007	The effect of 4 weeks treatment with desloratadine (5mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis.	desloratadine	37-50	interleukin 4	Homo sapiens	76-94
16530440-0	2007	The effect of 4 weeks treatment with desloratadine (5mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis.	desloratadine	37-50	interleukin 10	Homo sapiens	96-101
16530440-0	2007	The effect of 4 weeks treatment with desloratadine (5mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis.	desloratadine	37-50	interleukin 18	Homo sapiens	103-108
16530440-0	2007	The effect of 4 weeks treatment with desloratadine (5mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis.	desloratadine	37-50	transforming growth factor beta 1	Homo sapiens	113-121
16530440-1	2007	Anti-inflammatory effect of desloratadine (DL), including, but not limited to depression of production of IL-4, IL-6 and IL-8, has been shown in several in vitro experiments but only a few in vivo studies refer to this findings.	desloratadine	28-41	interleukin 4	Homo sapiens	106-110
16530440-1	2007	Anti-inflammatory effect of desloratadine (DL), including, but not limited to depression of production of IL-4, IL-6 and IL-8, has been shown in several in vitro experiments but only a few in vivo studies refer to this findings.	desloratadine	28-41	interleukin 6	Homo sapiens	112-116
16530440-1	2007	Anti-inflammatory effect of desloratadine (DL), including, but not limited to depression of production of IL-4, IL-6 and IL-8, has been shown in several in vitro experiments but only a few in vivo studies refer to this findings.	desloratadine	28-41	C-X-C motif chemokine ligand 8	Homo sapiens	121-125
16530440-1	2007	Anti-inflammatory effect of desloratadine (DL), including, but not limited to depression of production of IL-4, IL-6 and IL-8, has been shown in several in vitro experiments but only a few in vivo studies refer to this findings.	desloratadine	43-45	interleukin 4	Homo sapiens	106-110
16530440-1	2007	Anti-inflammatory effect of desloratadine (DL), including, but not limited to depression of production of IL-4, IL-6 and IL-8, has been shown in several in vitro experiments but only a few in vivo studies refer to this findings.	desloratadine	43-45	interleukin 6	Homo sapiens	112-116
16530440-1	2007	Anti-inflammatory effect of desloratadine (DL), including, but not limited to depression of production of IL-4, IL-6 and IL-8, has been shown in several in vitro experiments but only a few in vivo studies refer to this findings.	desloratadine	43-45	C-X-C motif chemokine ligand 8	Homo sapiens	121-125
16970513-1	2006	BACKGROUND AND OBJECTIVES: Desloratadine and levocetirizine are histamine H(1) receptor antagonists (antihistamines) that were launched in the UK in 2001.	desloratadine	27-40	histamine receptor H1	Homo sapiens	64-87
16650165-8	2006	Treatment with desloratadine caused a relevant reduction of ROS levels and SOD activity (P<0.005).	desloratadine	15-28	superoxide dismutase 1	Homo sapiens	75-78
16393266-0	2006	Effect of desloratadine on epithelial cell granulocyte-macrophage colony-stimulating factor secretion and eosinophil survival.	desloratadine	10-23	colony stimulating factor 2	Homo sapiens	43-91
16393266-11	2006	CONCLUSION: The inhibitory effects of DL on epithelial cell GM-CSF secretion and on eosinophil survival induced by epithelial cell secretions, suggest that this H(1) antagonist may regulate eosinophil inflammation in upper airways.	desloratadine	38-40	colony stimulating factor 2	Homo sapiens	60-66
16741367-7	2006	RESULTS: Desloratadine and loratadine inhibited the constitutive and IFN-gamma-induced release of CCL5, CXCL8 and CXCL10 from keratinocytes, while the low release of CCL17 remained unchanged.	desloratadine	9-22	interferon gamma	Homo sapiens	69-78
16741367-1	2006	BACKGROUND: Desloratadine is an H1-histamine antagonist which possesses additional anti-inflammatory properties through inhibition of leukocyte activation and reduction of ICAM-1 expression on mucosal epithelial cells.	desloratadine	12-25	intercellular adhesion molecule 1	Homo sapiens	172-178
16741367-7	2006	RESULTS: Desloratadine and loratadine inhibited the constitutive and IFN-gamma-induced release of CCL5, CXCL8 and CXCL10 from keratinocytes, while the low release of CCL17 remained unchanged.	desloratadine	9-22	C-C motif chemokine ligand 5	Homo sapiens	98-102
16741367-7	2006	RESULTS: Desloratadine and loratadine inhibited the constitutive and IFN-gamma-induced release of CCL5, CXCL8 and CXCL10 from keratinocytes, while the low release of CCL17 remained unchanged.	desloratadine	9-22	C-X-C motif chemokine ligand 8	Homo sapiens	104-109
16741367-3	2006	OBJECTIVE: In this study the capacity of desloratadine and loratadine to counteract human keratinocyte activation by interferon-gamma (IFN-gamma) was analyzed.	desloratadine	41-54	interferon gamma	Homo sapiens	117-133
16741367-7	2006	RESULTS: Desloratadine and loratadine inhibited the constitutive and IFN-gamma-induced release of CCL5, CXCL8 and CXCL10 from keratinocytes, while the low release of CCL17 remained unchanged.	desloratadine	9-22	C-X-C motif chemokine ligand 10	Homo sapiens	114-120
16741367-3	2006	OBJECTIVE: In this study the capacity of desloratadine and loratadine to counteract human keratinocyte activation by interferon-gamma (IFN-gamma) was analyzed.	desloratadine	41-54	interferon gamma	Homo sapiens	135-144
16741367-7	2006	RESULTS: Desloratadine and loratadine inhibited the constitutive and IFN-gamma-induced release of CCL5, CXCL8 and CXCL10 from keratinocytes, while the low release of CCL17 remained unchanged.	desloratadine	9-22	C-C motif chemokine ligand 17	Homo sapiens	166-171
16741367-9	2006	CONCLUSIONS: The results indicate that desloratadine has the capacity to block the IFN-gamma-induced activation of keratinocytes, and that it can thus exert important regulatory effects on cell-mediated immune responses in the skin.	desloratadine	39-52	interferon gamma	Homo sapiens	83-92
17877115-0	2005	[The effect of desloratadine on use of rescue beta2-agonists and symptoms in patients suffering from seasonal allergic rhinitis and asthma].	desloratadine	15-28	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	46-51
16275616-10	2005	RESULTS: Desloratadine and levocetirizine treatment induced significant symptom relief and significant reduction of IL-4.	desloratadine	9-22	interleukin 4	Homo sapiens	116-120
16259582-1	2005	Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist.	desloratadine	0-13	histamine receptor H1	Homo sapiens	70-91
15934291-5	2005	The immunoreactivity of iNOS had no significant difference between groups (P > 0.05), but eNOS had stronger immunoreactivity in the model group and the desloratadine treated group when compared with the negative control group (P < 0.01 and P < 0.05).	desloratadine	155-168	nitric oxide synthase, endothelial	Cavia porcellus	93-97
16429733-2	2005	In the present study, we aimed at observing whether IL-4 could be released from human mast cell line (HMC-1) after the stimulation of PMA + A23187, and the effects of systemic glucocorticosteroid, dexamethasone, topical glucocorticosteroid, budesonide and H1 antagonist, desloratadine on IL-4 release and mRNA expression.	desloratadine	271-284	interleukin 4	Homo sapiens	52-56
16429733-7	2005	Dexamethasone, budesonide and desloratadine had potent inhibitory effect on IL-4 release at any concentrations and time points, with significant deference (P < 0.05) compared to the control cells.	desloratadine	30-43	interleukin 4	Homo sapiens	76-80
16429733-9	2005	Desloratadine and budesonide showed neither up-regulatory nor down-regulatory effects on IL-4 mRNA expression at the test concentrations, however, desloratadine could down-regulate IL-4 mRNA expression.	desloratadine	147-160	interleukin 4	Homo sapiens	181-185
16429733-11	2005	Dexamethasone, budesonide and desloratadine all had inhibitory effects on IL-4 release from HMC-1.	desloratadine	30-43	interleukin 4	Homo sapiens	74-78
16429733-12	2005	In addition, desloratadine could also inhibit the IL-4 mRNA expression.	desloratadine	13-26	interleukin 4	Homo sapiens	50-54
15312146-12	2004	An interaction of desloratadine with P-gp has been suggested in mice, whereas the information on mizolastine is very poor.	desloratadine	18-31	phosphoglycolate phosphatase	Mus musculus	37-41
17523764-0	2005	Predicting and establishing the clinical efficacy of a histamine h(1)-receptor antagonist : desloratadine, the model paradigm.	desloratadine	92-105	histamine receptor H1	Homo sapiens	55-78
15564772-0	2004	Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-kappaB activity consistent with inverse agonism at the histamine H1 Receptor.	desloratadine	0-13	histamine receptor H1	Homo sapiens	131-152
15564772-8	2004	CONCLUSIONS: Desloratadine, acting through the histamine H1 receptor, inhibited basal NF-kappaB activity and can thus be classified as an inverse agonist.	desloratadine	13-26	histamine receptor H1	Homo sapiens	47-68
15496643-10	2004	Coadministration of desloratadine with a potent inhibitor of CYP2D6 did not result in clinically relevant changes in its pharmacokinetic parameters.	desloratadine	20-33	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	61-67
15168099-2	2004	Desloratadine is a potent, selective, histamine H(1)-receptor antagonist that does not easily cross the blood-brain barrier.	desloratadine	0-13	histamine receptor H1	Homo sapiens	38-61
12167464-0	2002	Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor.	desloratadine	32-45	histamine receptor H1	Homo sapiens	80-103
12584158-6	2003	In addition, certirizine, desloratadine, diphenhydramine, and triprolidine (2 microM) were tested as substrates for MDR1 using MDR1-MDCK cells.	desloratadine	26-39	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	116-120
12584158-9	2003	Likewise, the efflux ratio between basolateral to apical and apical to basolateral was 4.6- and 6.6-fold higher in MDR1-MDCK than the parental MDCK for certirizine and desloratadine, respectively, whereas it was approximately 1 for diphenhydramine and triprolidine.	desloratadine	168-181	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	115-119
12584158-11	2003	In contrast, nonsedating H1-antagonists cetirizine, loratadine, and desloratadine are P-gp substrates.	desloratadine	68-81	phosphoglycolate phosphatase	Mus musculus	86-90
12962522-1	2003	UNLABELLED: Desloratadine (Clarinex, Neoclarityn, Aerius, Azomyr, Opulis, Allex), the principal metabolite of loratadine, is itself an orally active, nonsedating, peripheral histamine H(1)-receptor antagonist.	desloratadine	12-25	histamine receptor H1	Homo sapiens	174-197
12392387-9	2002	Desloratadine reduced the nasal symptoms (P < 0.05 to 0.001) and output of fucose (P < 0.05 at 100 and 1,000 SQ-U) and alpha2-macroglobulin (P < 0.05 at 1,000 SQ-U).	desloratadine	0-13	alpha-2-macroglobulin	Homo sapiens	125-145
12167464-1	2002	We have characterized desloratadine (5H-benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene), CAS 100643-71-8) as a potent antagonist of the human histamine H(1) receptor.	desloratadine	22-35	histamine receptor H1	Homo sapiens	177-200
12167464-2	2002	[3H]Desloratadine bound to membranes expressing the recombinant human histamine H(1) receptor in Chinese hamster ovary cells (CHO-H(1)) in a specific and saturable manner with a K(d) of 1.1+/-0.2 nM, a B(max) of 7.9+/-2.0 pmol/mg protein, and an association rate constant of 0.011 nM(-1) x min(-1).	desloratadine	4-17	histamine receptor H1	Homo sapiens	70-93
12167464-4	2002	Dissociation of [3H]desloratadine from the human histamine H(1) receptor was slow, with only 37% of the binding reversed at 6 h in the presence of 5 microM unlabeled desloratadine.	desloratadine	20-33	histamine receptor H1	Homo sapiens	49-72
12167464-10	2002	The slow dissociation from the receptor and noncompetitive antagonism suggests that desloratadine may be a pseudoirreversible antagonist of the human histamine H(1) receptor.	desloratadine	84-97	histamine receptor H1	Homo sapiens	150-173
12167464-11	2002	The mechanism of desloratadine antagonism of the human histamine H(1) receptor may help to explain the high potency and 24-h duration of action observed in clinical studies.	desloratadine	17-30	histamine receptor H1	Homo sapiens	55-78
12492724-1	2002	Desloratadine, a potent, once-daily, orally active, nonsedating, histamine H1-receptor antagonist, inhibits the release of histamine and other inflammatory mediators.	desloratadine	0-13	histamine receptor H1	Homo sapiens	65-86
12492727-5	2002	In vitro studies show that desloratadine, a new, once-daily, nonsedating, selective histamine H1-receptor antagonist, blocks the systemic allergy cascade at multiple points.	desloratadine	27-40	histamine receptor H1	Homo sapiens	84-105
12492727-6	2002	Desloratadine 5 mg once daily relieves the symptoms of chronic idiopathic urticaria and of both seasonal (SAR) and perennial allergic rhinitis.	desloratadine	0-13	sarcosine dehydrogenase	Homo sapiens	106-109
12492727-7	2002	In patients with concomitant asthma and SAR, asthma symptoms are relieved and beta2-agonist medication use is decreased by desloratadine.	desloratadine	123-136	sarcosine dehydrogenase	Homo sapiens	40-43
12492727-7	2002	In patients with concomitant asthma and SAR, asthma symptoms are relieved and beta2-agonist medication use is decreased by desloratadine.	desloratadine	123-136	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	78-83
12492727-8	2002	Unlike many other second-generation histamine H1-receptor antagonists, desloratadine provides the added benefit of efficacy against nasal obstruction in SAR.	desloratadine	71-84	histamine receptor H1	Homo sapiens	36-57
12492727-8	2002	Unlike many other second-generation histamine H1-receptor antagonists, desloratadine provides the added benefit of efficacy against nasal obstruction in SAR.	desloratadine	71-84	sarcosine dehydrogenase	Homo sapiens	153-156